Gender and the use of neuroleptics in schizophrenia

Schizophrenia Research

Volumn 66, Issue 1, 2004, Pages 41-49

  Salokangas, Raimo K R ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b Turku Psychiatric Clinic   (Finland)

Author keywords

Age; Age of onset; Daily doses of neuroleptics; Estrogens; Gender; Schizophrenia; Testosterones

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CLOTIAPINE; CLOZAPINE; ESTROGEN; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; SEDATIVE AGENT; THIORIDAZINE; TRANQUILIZER; ZUCLOPENTHIXOL;

ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE;

EID: 0348226479     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00530-3     Document Type: Article

References (51)

1. Abe T., Yama Y., Wada Y., Suzuki M. Pituitary-ovarian relationships in women approaching the menopause. Maturitas. 5:1983;31-37.
2. Alanen Y.O., Räkköläinen V., Laakso J., Rasimus R., Kaljonen A. Towards Need-Spesific Treatment of Schizophrenic Psychoses. 1986;Springer-Verlag, Heidelberg.
3. Angermeyer M.C., Kühn L. Gender differences in age at onset of schizophrenia. An overview. Eur. Arch. Psychiatry Neurol. Sci. 237:1988;351-364.
4. Angermeyer M.C., Goldstein J.M., Kuehn L. Gender differences in schizophrenia: rehospitalization and community survival. Psychol. Med. 19:1989;365-382.
5. Bland R.C., Orn H. 14-Year outcome in early schizophrenia. Acta Psychiatr. Scand. 58:1978;327-338.
6. Brenner P.F. The menopause. West. J. Med. 136:1982;211-219.
7. Carpenter W.T. Jr., Heinrichs D.W., Wagman A.M.I. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry. 145:1988;578-583.
8. Davidson J.M., Chen J.J., Crapo L., Graym G.D., Greenleafm W.J., Cataniam J.A. Hormonal changes and sexual function in aging men. J. Clin. Endocr. Metab. 57:1983;71-77.
9. Endicott J., Spitzer R.L., Fleis J.L., Cohen J. The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 33:1976;766-771.
10. Farina A. Are women nicer people then men? Sex and the stigma of mental disorders. Clin. Psychol. Rev. 1:1981;223-243.
11. Häfner H., Riecher A., Mauer K., Löffler W., Munk-Jörgensen P., Strömgren E. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. Psychol. Med. 19:1989;903-918.
12. Häfner H., Behrens S., De-Vry J., Gattaz W.F. Öestradiol enhances the vulnerability threshold for schizophrenia in women by early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur. Arch. Psychiatry Clin. Neurosci. 241:1991;65-68.
13. Haring C., Meise U., Humpel C., Saria A., Fleischhacker W.W., Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behavior, sex, and age. Psychopharmacology. 99:1989;S38-S40.
14. Herran A., de-Santiago A., Sandoya M., Fernandez M.J., Diez-Manrique J.F., Vazquez-Barquero J.L. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr. Res. 41:2000;373-381.
15. Honkonen T., Saarinen S., Salokangas R.K.R. Deinstitutionalization and schizophrenia in Finland II: discharged patients and their psychosocial functioning. Schizophr. Bull. 25:1999;547-555.
16. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 143:1986;993-997.
17. Inoue M., Suhara T., Sudo Y., Okubo Y., Yasuno F., Kishimoto T., Yoshikawa K., Tanada S. Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci. 69:2001;1079-1084.
18. Jann M., Saklad S.R., Ereshefsky L., Richards A.L., Harington C.A., Davis C.M. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology. 90:1986;468-470.
19. Kaasinen V., Vilkman H., Hietala J., Nagren K., Helenius H., Olsson H., Farde L., Rinne J. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol. Aging. 21:2000;683-688.
20. Kaneda Y., Fujii A. Effects of chronic neuroleptic admisnistration on the hypothalamo-pituarity-gonadal axis of male schizophrenics. Prog. Neuropsychopharmacol. Biol. Psychiatry. 24:2000;251-258.
21. Krailo M.D., Pike M.C. Estimation of the distribution of age at natural menopause from prevalence data. Am. J. Epidemiol. 117:1983;356-361.
22. Krakowski M., Volavka J., Brizer D. Psychopathology and violence: a review of literature. Compr. Psychiat. 27:1986;131-148.
23. Lohr J.B., Flynn K. Smoking and schizophrenia. Schizophr. Res. 8:1992;93-102.
24. Longcope C., Franz C., Morello C., Baker R., Johnston C.C. Jr. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas. 10:1988;189-198.
25. Lääkintöhallitus, 1986. Tautiluokitus 1987. (Classification of diseases 1987.) Helsinki: Valtion painatuskeskus.
26. McGuire M.T., Troisi A. Aggression. Kaplan H.I., Sadock B.J. Comprehensive Textbook of Psychiatry. 5th ed. 1989;271-282 Williams and Wilkins, Baltimore.
27. Miller R.R. Effects of smoking on drug action. Clin. Pharmacol. Ther. 22:1977;749-756.
28. Mozley L.H., Gur R.C., Mozley D., Gur R.E. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am. J. Psychiatry. 158:2001;1492-1499.
29. Murphy D.G.M., DeCarli C., McIntosh A.R., Daly E., Mentis J.M., Pietrini P., Szczepanik J., Schapiro M.B., Grady C.L., Horwitz B., Rapoport S.I. Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on effect of aging. Arch. Gen. Psychiatry. 53:1996;585-594.
30. Räsänen P., Hakko H., Visuri S., Paanila J., Kapanen P., Suomela T., Tiihonen J. Serum testosterone levels, mental disorders and criminal behaviour. Acta Psychiatr. Scand. 99:1999;346-352.
31. Riecher-Rössler A., Häfner H. Schizophrenia and oestrogens - is there an association? Eur. Arch. Psychiatry Clin. Neurosci. 242:1993;223-328.
32. Salokangas R.K.R. Psychosocial prognosis in schizophrenia. Formation of the prognosis for schizophrenic patients: a multivariate analysis. 1978;Annales Universitatis Turkuensis ser D 9, Turku.
33. Salokangas R.K.R. Prognostic implications of the sex of schizophrenic patients. Br. J. Psychiatry. 142:1983;145-151.
34. Salokangas R.K.R. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr. Res. 16:1995;7-16.
35. Salokangas R.K.R., Saarinen S. Deinstitutionalisation and schizophrenia in Finland: discharged patients and their care. A follow-up study of schizophrenic patients discharged from Finnish mental hospitals in 1982, 1986 and 1990. Schizophr. Bull. 24:1998;457-467.
36. Salokangas R.K.R., Stengård E. Gender and short-term outcome in schizophrenia. Schizophr. Res. 3:1990;333-345.
37. Salokangas R.K.R., Saarijärvi S., Taiminen T., Lehto H., Niemi H., Ahola V., Syvälahti E. Effect of smoking on neuroleptics in schizophrenia. Schizophr. Res. 23:1997;55-60.
38. Salokangas, R.K.R., Stengård, E., Honkonen, T., Koivisto, A.-M., Saarinen, S., 2000. Sairaalasta yhteiskuntaan. (From Hospital to the Community; Finnish report). STAKES, Raportteja 248, Helsinki.
39. Salokangas R.K.R., Honkonen T., Stengård E. Discharged schizophrenia patients in the community - implications for service development. A follow-up study of schizophrenia patients discharged from Finnish mental hospitals in 1982, 1986, 1990 and 1994. Psychiatria Fennica Suppl. 2:2001;111-122.
40. Sartorius N., Jablensky A., Korten A., Ernberg G., Anker M., Cooper J.E., Day R. Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol. Med. 16:1986;909-928.
41. Schlosser R., Brodie J.D., Dewey S.-L., Alexoff D., Wang G.J., Fowler J.S., Volkow N., Logan J., Wolf A.P. Long-term stability of neurotransmitter activity investigated with 11C-raclopride PET. Synapse. 28:1998;66-70.
42. Seeman M.V. Interaction of sex, age, and neuroleptic dose. Compr. Psychiatry. 24:1983;125-128.
43. Seeman M.V. Current outcome in schizophrenia: women vs men. Acta Psychiatr. Scand. 73:1986;609-617.
44. Seeman M.V., Lang M. The role of estrogens in schizophrenia gender differences. Schizophr. Bull. 16:1990;185-194.
45. Shepherd M., Watt D., Falloon I., Smeeton N. The natural history of schizophrenia: a five year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol. Med. Monogr. Suppl. 15:1989.
46. Sherman B.M., Korenman S.G. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J. Clin. Invest. 55:1975;699-706.
47. Stearns E.L., MacDonnel J.A., Kaufman B.J., Padua R., Lucman T.S., Winter J.S.D., Faiman C. Declining testicular function with age. Am. J. Med. 57:1974;761-766.
48. Wattie B.J.S., Kedward H.B. Gender differences in living conditions found among male and female schizophrenic patients on a follow-up study. Int. J. Soc. Psychiatry. 31:1985;205-216.
49. Virkkunen M., Rawlings R., Tokola R., Poland R., Guidotti A., Nemeroff C., Bissette G., Kalogeras K., Karonen S.-L., Linnoila M. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch. Gen. Psychiatry. 51:1994;20-27.
50. Wyatt R.J. Biochemistry and Schizophrenia (Part IV). The neuroleptics - their mechanism of action: a review of the biochemical literature. Psychopharmacol. Bull. 12:1976;5-55.
51. Ziedonis D.M., Kosten T.R., Glazer W.M., Frances R.J. Nicotine dependence and schizophrenia. Hosp. Com. Psychiatry. 45:1994;204-206.